Begin open label extension study for REDWOOD-HCM completers
Delivered by the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 25 Feb 2021
- Due
- 30 Jun 2021
- Delivered
- 6 May 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Expect to begin an open label extension study for patients who complete REDWOOD-HCM in Q2 2021.”
What we found
Evidence strength A What the grades mean
Filings state that on May 6, 2021 the company announced the first site was activated to enroll patients in the REDWOOD-HCM OLE, within Q2 2021.
-
A Cytokinetics Inc. 8-K filed 2021-07-19
“REDWOOD-HCM OLE open for eligible patients who completed REDWOOD-HCM” ✓ confirmed on the page
-
A Cytokinetics Inc. 10-Q filed 2021-08-06
“On May 6, 2021, we announced that the first site had been activated to enroll patients in REDWOOD-HCM OLE, an open-label extension clinical study” ✓ confirmed on the page
Checked 26 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Begin
- Deliverable
- Open label extension study of CK-274
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Cytokinetics Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-CYTK-024466 · Corrections policy